



ASX RELEASE (12 MAY 2023)

MEDICINAL CANNABIS PERMIT RENEWED

Epsilon Healthcare Limited (ASX:EPN) the COMPANY, are pleased to announce that the Medicinal Cannabis Permit issued to wholly owned operating subsidiary, THC Pharma Pty Ltd has been successfully renewed.

In addition, the Office of Drug Control (ODC) has granted the company increased manufacturing quantities to meet the growing demand from our clients as shown by a ramp-up in activities reported for the 2022 period.

The EPN Board particularly thank the hard work and dedication of our team, who have been able to increase our manufacturing to meet the growing demand for our medicines.

We are proud of the progress we have made so far. The increase in the manufacturing quantities granted by ODC, due to increased client demand, is testimony to our commitment to excellence. It also demonstrates our ability to adapt to the changing needs of the industry and our client demand, operating as a toll manufacturer.

As we continue to grow, we remain committed to delivering our clients and patients with the highest quality medicines possible and the exceptional level of care that they come to expect from us, especially given the new TGA reforms to apply from July.

ENDS

This announcement has been approved for release by the Board of Directors.

For further information, please contact:



Josh Cui
Chairman
e: corporate@epsilonhc.com

Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare (ASX:EPN) is a diversified global healthcare and pharmaceuticals company. EPN owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport Facility) and the Tetra Health clinic group.